Insmed Incorporated (INSM) Stock Score, Valuation & Financial Research
Insmed Incorporated is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for INSM
Insmed Incorporated currently has a Wall Street Score of 25/100. The stored market price is $129.41. Its financial score is 20/100. Its valuation score is 0/100. The latest WSS change is -2.0 points. These figures are a research snapshot, not a buy or sell recommendation.
What Insmed Incorporated does
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintai
INSM financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $129.41
- Market capitalization:
- $28.05B
- Revenue:
- $1.14B
- Net income:
- $-875.3M
- Free cash flow:
- $-967.6M
- Cash:
- $544.8M
- Total debt:
- $579.9M
- EPS:
- -6.41
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 40/100
What stands out
- Reported year-over-year revenue growth is +0.9%.
- Free cash flow is $-967.6M, showing cash burn in the current stored period.
- The balance sheet shows $544.8M of cash versus $579.9M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -2.0 points: INSM decreased 2 points because Debt declined by 20.1 points, Buffett declined by 5.1 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research INSM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.